Development and Characterization of a Microemulsion Containing a Cannabidiol Oil and a Hydrophilic Extract from for Topical Administration

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2024 Jun 27

PMID 38931831

Authors

Teresa Areses-Huete

Damian Cordoba-Diaz

Ana Isabel Torres-Suarez

Manuel Cordoba-Diaz

Affiliations

Soon will be listed here.

Abstract

Cannabidiol (CBD) is a safe and non-psychotropic phytocannabinoid with a wide range of potential therapeutic anti-inflamatory and antioxidant activities. Due to its lipophilicity, it is normally available dissolved in oily phases. The main aim of this work was to develop and characterize a new formulation of a microemulsion with potential anti-inflammatory and antioxidant activity for the topical treatment of inflammatory skin disorders. The microemulsion system was composed of a 20% CBD oil, which served as the hydrophobic phase; Labrasol/Plurol Oleique (1:1), which served as surfactant and cosurfactant (S/CoS), respectively; and an aqueous vegetal extract obtained from L. () ripe fruits, which has potential anti-oxidant and anti-inflammatory activity and which served as the aqueous phase. A pseudo-ternary phase diagram was generated, leading to the selection of an optimal proportion of 62% (S/CoS), 27% CBD oil and 11% water and, after its reproducibility was tested, the aqueous phases were replaced by the vegetal hydrophilic extract. The defined systems were characterized in terms of conductivity, droplet size (by laser scattering), compatibility of components (by differential scanning calorimetry) and rheological properties (using a rotational rheometer). The designed microemulsion showed good stability and slight pseudo-plastic behavior. The release properties of CBD from the oil phase and caffeic acid from the aqueous phase of the microemulsion were studied via in vitro diffusion experiments using flow-through diffusion cells and were compared to those of a CBD oil and a microemulsion containing only CBD as an active substance. It was found that the inclusion of the original oil in microemulsions did not result in a significant modification of the release of CBD, suggesting the possibility of including hydrophilic active compounds in the formulation and establishing an interesting strategy for the development of future formulations.

References

Pisanti S, Malfitano A, Ciaglia E, Lamberti A, Ranieri R, Cuomo G . Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017; 175:133-150. DOI: 10.1016/j.pharmthera.2017.02.041. View

Grotenhermen F, Muller-Vahl K . The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int. 2012; 109(29-30):495-501. PMC: 3442177. DOI: 10.3238/arztebl.2012.0495. View

Eagleston L, Kalani N, Patel R, Flaten H, Dunnick C, Dellavalle R . Cannabinoids in dermatology: a scoping review. Dermatol Online J. 2018; 24(6). View

Russo E, Burnett A, Hall B, Parker K . Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005; 30(8):1037-43. DOI: 10.1007/s11064-005-6978-1. View

Del Rio C, Millan E, Garcia V, Appendino G, DeMesa J, Munoz E . The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. Biochem Pharmacol. 2018; 157:122-133. DOI: 10.1016/j.bcp.2018.08.022. View

Kogan A, Garti N . Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interface Sci. 2006; 123-126:369-85. DOI: 10.1016/j.cis.2006.05.014. View

Baswan S, Klosner A, Glynn K, Rajgopal A, Malik K, Yim S . Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders. Clin Cosmet Investig Dermatol. 2020; 13:927-942. PMC: 7736837. DOI: 10.2147/CCID.S286411. View

Besner Morin C, Misery L . Emerging Treatments and Novel Pathways in Pruritus. J Cutan Med Surg. 2019; 23(5):528-536. DOI: 10.1177/1203475419852050. View

Makhakhe L . Topical cannabidiol (CBD) in skin pathology - A comprehensive review and prospects for new therapeutic opportunities. S Afr Fam Pract (2004). 2022; 64(1):e1-e4. PMC: 9210160. DOI: 10.4102/safp.v64i1.5493. View

10.

Sclafani J, Nightingale J, Liu P . Flow-through system effects on in vitro analysis of transdermal systems. Pharm Res. 1993; 10(10):1521-6. DOI: 10.1023/a:1018943929902. View

11.

Battista N, Di Tommaso M, Bari M, Maccarrone M . The endocannabinoid system: an overview. Front Behav Neurosci. 2012; 6:9. PMC: 3303140. DOI: 10.3389/fnbeh.2012.00009. View

12.

Ahmadiani A, Fereidoni M, Semnanian S, Kamalinejad M, Saremi S . Antinociceptive and anti-inflammatory effects of Sambucus ebulus rhizome extract in rats. J Ethnopharmacol. 1998; 61(3):229-35. DOI: 10.1016/s0378-8741(98)00043-9. View

13.

Farahani A, Aryanian Z, Memariani Z, Mozaffarpur S, Shirafkan H . A Comparison of the Effect of Topical Preparation of L. and Hydrocortisone on Hand Eczema: A Double-Blind Randomized Controlled Trial. J Altern Complement Med. 2021; 27(4):323-330. DOI: 10.1089/acm.2020.0343. View

14.

Zielinska A, Cano A, Andreani T, Martins-Gomes C, Silva A, Szalata M . Lipid-Drug Conjugates and Nanoparticles for the Cutaneous Delivery of Cannabidiol. Int J Mol Sci. 2022; 23(11). PMC: 9180973. DOI: 10.3390/ijms23116165. View

15.

Pavaloiu R, Shaat F, Bubueanu C, Deaconu M, Neagu G, Shaat M . Polyphenolic Extract from L. Leaves Free and Loaded into Lipid Vesicles. Nanomaterials (Basel). 2019; 10(1). PMC: 7023427. DOI: 10.3390/nano10010056. View

16.

Xu D, Cullen B, Tang M, Fang Y . The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. Curr Pharm Biotechnol. 2019; 21(5):390-402. DOI: 10.2174/1389201020666191202111534. View

17.

Calderon L, Harris R, Cordoba-Diaz M, Elorza M, Elorza B, Lenoir J . Nano and microparticulate chitosan-based systems for antiviral topical delivery. Eur J Pharm Sci. 2012; 48(1-2):216-22. DOI: 10.1016/j.ejps.2012.11.002. View

18.

Junaid M, Tijani A, Puri A, Banga A . In vitro percutaneous absorption studies of cannabidiol using human skin: Exploring the effect of drug concentration, chemical enhancers, and essential oils. Int J Pharm. 2022; 616:121540. DOI: 10.1016/j.ijpharm.2022.121540. View

19.

Kupczyk P, Reich A, Szepietowski J . Cannabinoid system in the skin - a possible target for future therapies in dermatology. Exp Dermatol. 2009; 18(8):669-79. DOI: 10.1111/j.1600-0625.2009.00923.x. View

20.

Ebrahimzadeh M, Nabavi S, Nabavi S . Antioxidant activities of methanol extract of Sambucus ebulus L. flower. Pak J Biol Sci. 2009; 12(5):447-50. DOI: 10.3923/pjbs.2009.447.450. View